Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $40.8 million versus the consensus estimate of $38.44 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• Jack Henry (JKHY) Tops Q4 EPS by 13c